The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
Liu, W., Putnam, A. L., Xu-yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. A., Kapranov, P., Gingeras, T. R., de St. Groth, B. F., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060772 · Cited by 2,606
Seddiki, N., Santner-Nanan, B., Martinson, J., Zaunders, J., Sasson, S., Landay, A., Solomon, M., Selby, W., Alexander, S. I., Nanan, R., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060468 · Cited by 1,512
Transient expression of FOXP3 in human activated nonregulatory CD4 + T cells
Wang, J., Ioan‐Facsinay, A., van der Voort, E. I. H., Huizinga, T. W. J., & Toes, R. E. M. (2007) · European Journal of Immunology · doi:10.1002/eji.200636435 · Cited by 1,011
CD24 and Siglec-10 Selectively Repress Tissue Damage–Induced Immune Responses
Chen, G.-Y., Tang, J., Zheng, P., & Liu, Y. (2009) · Science · doi:10.1126/science.1168988 · Cited by 786
Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis
Coles, A. J., Wing, M., Smith, S., Coraddu, F., Greer, S., Taylor, C., Weetman, A., Hale, G., Chatterjee, V. K., Waldmann, H., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02429-0 · Cited by 453
Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
Cossburn, M., Pace, A. A., Jones, J., Ali, R., Ingram, G., Baker, K., Hirst, C., Zajicek, J., Scolding, N., Boggild, M., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318228bec5 · Cited by 216
Loss of Siglec expression on T lymphocytes during human evolution
Nguyen, D. H., Hurtado-Ziola, N., Gagneux, P., & Varki, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510484103 · Cited by 204
Cited by
Siglec-mediated regulation of immune cell function in disease
Macauley, M. S., Crocker, P. R., & Paulson, J. C. (2014) · Nature Reviews Immunology · doi:10.1038/nri3737 · Cited by 1,122
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
Smith, B. A. H., & Bertozzi, C. R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00093-1 · Cited by 500
Immunology of Relapse and Remission in Multiple Sclerosis
Steinman, L. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120227 · Cited by 330
Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells
Stanczak, M. A., Siddiqui, S. S., Trefny, M. P., Thommen, D. S., Boligan, K. F., von Gunten, S., Tzankov, A., Tietze, L., Lardinois, D., Heinzelmann-Schwarz, V., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120612 · Cited by 296
Emerging phagocytosis checkpoints in cancer immunotherapy
Liu, Y., Wang, Y., Yang, Y., Weng, L., Wu, Q., Zhang, J., Zhao, P., Fang, L., Shi, Y., & Wang, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01365-z · Cited by 275
Solís, D., Bovin, N. V., Davis, A. P., Jiménez-Barbero, J., Romero, A., Roy, R., Smetana, K., & Gabius, H.-J. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.03.016 · Cited by 222
Zhu, H., Galdos, F. X., Lee, D., Waliany, S., Huang, Y. V., Ryan, J., Dang, K., Neal, J. W., Wakelee, H. A., Reddy, S. A., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.056730 · Cited by 192
Sialic Acid Mimetics to Target the Sialic Acid–Siglec Axis
Büll, C., Heise, T., Adema, G. J., & Boltje, T. J. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2016.03.007 · Cited by 165
Sweet escape: Sialic acids in tumor immune evasion
Büll, C., den Brok, M. H., & Adema, G. J. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.07.005 · Cited by 158
Siglec-G/10 in self-nonself discrimination of innate and adaptive immunity
Chen, G.-Y., Brown, N. K., Zheng, P., & Liu, Y. (2014) · Glycobiology · doi:10.1093/glycob/cwu068 · Cited by 90
Vincenti, I., Page, N., Steinbach, K., Yermanos, A., Lemeille, S., Nunez, N., Kreutzfeldt, M., Klimek, B., Di Liberto, G., Egervari, K., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl6058 · Cited by 70
Xiao, N., Zhu, X., Li, K., Chen, Y., Liu, X., Xu, B., Lei, M., Xu, J., & Sun, H.-C. (2021) · Experimental Hematology & Oncology · doi:10.1186/s40164-021-00230-5 · Cited by 61
The intriguing roles of Siglec family members in the tumor microenvironment
Jiang, K.-Y., Qi, L.-L., Kang, F.-B., & Wang, L. (2022) · Biomarker Research · doi:10.1186/s40364-022-00369-1 · Cited by 43
Samten, B. (2013) · Cellular & Molecular Immunology · doi:10.1038/cmi.2013.38 · Cited by 24
ADTnorm: Robust Integration of Single-cell Protein Measurement across CITE-seq Datasets
Zheng, Y., Caron, D. P., Kim, J. Y., Jun, S.-H., Tian, Y., Florian, M., Stuart, K. D., Sims, P. A., & Gottardo, R. (2022) · doi:10.1101/2022.04.29.489989 · Cited by 18
Anti-CD52 Therapy for Multiple Sclerosis: An Update in the COVID Era
Kasarello, K., & Mirowska-Guzel, D. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s240890 · Cited by 11
Metadata
- Authors
- Bandala-Sanchez, E., Zhang, Y., Reinwald, S., Dromey, J. A., Lee, B.-H., Qian, J., Böhmer, R. M., & Harrison, L. C.
- Venue
- Nature Immunology
- Published
- 2013-05-19
- Volume
- 14
- Issue
- 7
- Pages
- 741-748
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- OpenAlex
- W2065750747
- Cited by
- 198
- References
- 9
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.